CEBPA and lung cancer: Furthermore, the ChIP assay was repeated in lung cancer cell lines with or without 5‐Aza‐CdR, and we found that the binding strength of C/EBPα to the GRK6 gene promoter increased significantly in the 5‐Aza‐CdR treatment group, compared with the untreated group (Fig. 5E,F).